Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

By S. Kopetz, G. Chang, M. Overman, C. Eng, D. Sargent, D. Larson, A. Grothey, J. Vauthey, D. Nagorney, R. McWilliams. Journal of Clinical Oncology, 2009

1,275 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/35eb26413a2359f2ddfb04ee1175e43eab239896

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. A. Jemal

In Hepatology

1. A. Jemal
2. Elizabeth E. Ward
3. Michel Ducreux

In Oncology

1. A. Jemal
2. Elizabeth E. Ward
3. R. Siegel
4. K. Miller
5. F. Bray
6. J. Ferlay

Citations in the corpus

• Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer (2011, background): “Median survival for metastatic CRC has improved from 10 months to >20 months with the development of new chemotherapeutic (oxaliplatin and irinotecan) and molecularly targeted agents (bevacizumab, cetuximab, and panitumumab).(2) Significant advances in molecular biology have driven rational developm”
• Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors (2012, background): “Because study size is likely to be related directly to the annual volume of patients seen at a liver-resection center (eg, see 20 ), and with the volume of patients seen annually related to survival, a cumulative meta-analysis based on annual clinic volume size by study center per year (ie, number…”
• Annual Report to the Nation on the Status of Cancer, 1975–2006, Featuring Colorectal Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates (2010, background): “Also, surgical resection of hepatic metastases and, more recently, the development of new chemotherapies appear to increase survival for patients with metastatic disease.(150,151) Targeted therapies with monoclonal antibodies have been developed(152) as well as more individualized CRC therapies base”
• Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017, background): “Only 20% to 30% of patients with CRC metastases confined to the liver are candidates for surgery (2,4).”